Midkine and syndecan‑1 levels correlate with the progression of malignant gastric cardiac adenocarcinoma

Hu,Xiu‑Feng; Yao,Jun; Gao,She‑Gan; Yang,Yan‑Tong; Peng,Xiu‑Qing; Feng,Xiao‑Shan

doi:10.3892/mmr.2014.2369

Midkine and syndecan‑1 levels correlate with the progression of malignant gastric cardiac adenocarcinoma

Authors:
- Xiu‑Feng Hu
- Jun Yao
- She‑Gan Gao
- Yan‑Tong Yang
- Xiu‑Qing Peng
- Xiao‑Shan Feng
View Affiliations

Affiliations: Department of Oncology, Cancer Research Institute, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 471003, P.R. China
Published online on: July 9, 2014 https://doi.org/10.3892/mmr.2014.2369
Pages: 1409-1415

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to determine whether the expression levels of midkine (MK) and syndecan‑1 correlate with the malignant progression and poor prognosis of gastric cardiac adenocarcinoma (GCA). GCA tissue samples (n=72) were obtained from the Department of Pathology of the First Affiliated Hospital of Henan University of Science and Technology (Luoyang, China). The paraffin‑embedded samples had been surgically resected and pathologically diagnosed between 2007 and 2009. Normal gastric cardiac biopsy specimens (n=40) were also collected as the control. The expression levels of MK and syndecan‑1 were assessed by immunohistochemistry using the high‑sensitivity streptavidin‑peroxidase method. Statistical analysis was performed on the data obtained using the SPSS 17.0 statistics package. MK expression was detected in 76.4% of GCA samples and 5% of normal gastric cardiac mucosa specimens. A significant positive correlation was observed between the expression levels of MK and the infiltrative depth of the tumor, the presence of lymph node metastasis and the prognosis of the patients (P<0.05). Syndecan‑1 expression was detected in 38.9% of GCA samples and 100% of normal gastric cardiac mucosa samples. The expression levels of syndecan‑1 were negatively correlated with the grade of differentiation, serosal membrane invasion, lymph node metastasis and the patient's prognosis (P<0.05). Notably, the expression levels of MK and syndecan‑1 were inversely correlated (r=‑0.352, P<0.01) in the GCA tissue samples. These results suggest that high expression levels of MK in GCA tissues may indicate a differentiation stage that is characteristic of malignancy, a late clinical stage and a poor prognosis, whereas increased syndecan‑1 levels may indicate a high degree of differentiation, an early clinical stage and a favorable prognosis. MK and syndecan‑1 may serve as important biomarkers for monitoring the development and progression of GCA.

View Figures

View References

1	Wang LD, Qin YR, Fan ZM, et al: Comparative genomic hybridization: comparison between esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-incidence area for both cancers in Henan, northern China. Dis Esophagus. 19:459–467. 2006. View Article : Google Scholar
2	Devesa SS, Blot WJ and Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 83:2049–2053. 1998. View Article : Google Scholar : PubMed/NCBI
3	Botterweck AA, Schouten LJ, Volovics A, Dorant E and van Den Brandt PA: Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. 29:645–654. 2000. View Article : Google Scholar : PubMed/NCBI
4	Kadomatsu K and Muramatsu T: Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 204:127–143. 2004. View Article : Google Scholar : PubMed/NCBI
5	Zhao ZQ, Yang S and Lu HS: Expression of midkine and vascular endothelial growth factor in gastric cancer and the association of high levels with poor prognosis and survival. Mol Med Rep. 5:415–419. 2012.PubMed/NCBI
6	Huang Y, Cao G, Wang H, Wang Q and Hou Y: The expression and location of midkine in gastric carcinomas of Chinese patients. Cell Mol Immunol. 4:135–140. 2007.PubMed/NCBI
7	Muramatsu T: Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 86:410–425. 2010. View Article : Google Scholar : PubMed/NCBI
8	Muramatsu T: Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis. J Biochem. 132:359–371. 2002. View Article : Google Scholar : PubMed/NCBI
9	Mitsiadis TA, Salmivirta M, Muramatsu T, et al: Expression of the heparin-binding cytokines, midkine (MK) and HB-GAM (pleiotrophin) is associated with epithelial-mesenchymal interactions during fetal development and organogenesis. Development. 121:37–51. 1995.
10	Bernfield M, Kokenyesi R, Kato M, et al: Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol. 8:365–393. 1992. View Article : Google Scholar : PubMed/NCBI
11	Teng YH, Aquino RS and Park PW: Molecular functions of syndecan-1 in disease. Matrix Biol. 31:3–16. 2012. View Article : Google Scholar : PubMed/NCBI
12	Anttonen A, Kajanti M, Heikkilä P, Jalkanen M and Joensuu H: Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br J Cancer. 79:558–564. 1999. View Article : Google Scholar : PubMed/NCBI
13	Hirabayashi K, Numa F, Suminami Y, et al: Altered proliferative and metastatic potential associated with increased expression of syndecan-1. Tumour Biol. 19:454–463. 1998. View Article : Google Scholar : PubMed/NCBI
14	Harada K, Masuda S, Hirano M and Nakanuma Y: Reduced expression of syndecan-1 correlates with histologic dedifferentiation, lymph node metastasis, and poor prognosis in intrahepatic cholangiocarcinoma. Hum Pathol. 34:857–863. 2003. View Article : Google Scholar
15	Wu X, Chen VW, Andrews PA, Ruiz B and Correa P: Incidence of esophageal and gastric cancers among Hispanics, non-Hispanic whites and non-Hispanic blacks in the United States: subsite and histology differences. Cancer Causes Control. 18:585–593. 2007. View Article : Google Scholar
16	Wijetunge S, Ma Y, DeMeester S, et al: Association of adenocarcinomas of the distal esophagus, ‘gastroesophageal junction,’ and ‘gastric cardia’ with gastric pathology. Am J Surg Pathol. 34:1521–1527. 2010.PubMed/NCBI
17	Xiao ZY, Ru Y, Sun JT, et al: Expression of CDX2 and villin in gastric cardiac intestinal metaplasia and the relation with gastric cardiac carcinogenesis. Asian Pac J Cancer Prev. 13:247–250. 2012. View Article : Google Scholar : PubMed/NCBI
18	Ding GC, Ren JL, Chang FB, et al: Human papillomavirus DNA and P16(INK4A) expression in concurrent esophageal and gastric cardia cancers. World J Gastroenterol. 16:5901–5906. 2010. View Article : Google Scholar : PubMed/NCBI
19	Chu YQ, Ye ZY, Tao HQ, et al: Relationship between cell adhesion molecules expression and the biological behavior of gastric carcinoma. World J Gastroenterol. 14:1990–1996. 2008. View Article : Google Scholar : PubMed/NCBI
20	Obata Y, Kikuchi S, Lin Y, et al: Serum midkine concentrations and gastric cancer. Cancer Sci. 96:54–56. 2005. View Article : Google Scholar : PubMed/NCBI
21	Sakamoto K and Kadomatsu K: Midkine in the pathology of cancer, neural disease, and inflammation. Pathol Int. 62:445–455. 2012. View Article : Google Scholar : PubMed/NCBI
22	Michikawa M, Kikuchi S, Muramatsu H, Muramatsu T and Kim SU: Retinoic acid responsive gene product, midkine, has neurotrophic functions for mouse spinal cord and dorsal root ganglion neurons in culture. J Neurosci Res. 35:530–539. 1993. View Article : Google Scholar : PubMed/NCBI
23	Shimada H, Nabeya Y, Okazumi S, et al: Increased serum midkine concentration as a possible tumor marker in patients with superficial esophageal cancer. Oncol Rep. 10:411–414. 2003.PubMed/NCBI
24	Xu YY, Mao XY, Song YX, et al: Midkine confers Adriamycin resistance in human gastric cancer cells. Tumour Biol. 33:1543–1548. 2012. View Article : Google Scholar : PubMed/NCBI
25	Krzystek-Korpacka M, Diakowska D, Grabowski K and Gamian A: Tumor location determines midkine level and its association with the disease progression in colorectal cancer patients: a pilot study. Int J Colorectal Dis. 27:1319–1324. 2012. View Article : Google Scholar
26	Hung YJ, Lin ZH, Cheng TI, Liang CT, Kuo TM and Kao KJ: Serum midkine as a prognostic biomarker for patients with hepatocellular carcinoma. Am J Clin Pathol. 136:594–603. 2011. View Article : Google Scholar : PubMed/NCBI
27	Zhao G, Nie Y, Lv M, He L, Wang T and Hou Y: ERβ-mediated estradiol enhances epithelial mesenchymal transition of lung adenocarcinoma through increasing transcription of midkine. Mol Endocrinol. 26:1304–1315. 2012.
28	Ibusuki M, Fujimori H, Yamamoto Y, et al: Midkine in plasma as a novel breast cancer marker. Cancer Sci. 100:1735–1739. 2009. View Article : Google Scholar : PubMed/NCBI
29	Reiff T, Huber L, Kramer M, Delattre O, Janoueix-Lerosey I and Rohrer H: Midkine and Alk signaling in sympathetic neuron proliferation and neuroblastoma predisposition. Development. 138:4699–4708. 2011. View Article : Google Scholar : PubMed/NCBI
30	Fabri L, Maruta H, Muramatsu H, et al: Structural characterisation of native and recombinant forms of the neurotrophic cytokine MK. J Chromatogr. 646:213–225. 1993. View Article : Google Scholar : PubMed/NCBI
31	Zhao ZQ, Yang S, Lu HS, et al: Expression of midkine and vascular endothelial growth factor in gastric cancer and the association of high levels with poor prognosis and survival. Mol Med Rep. 5:415–419. 2012.PubMed/NCBI
32	Teng YH, Aquino RS and Park PW: Molecular functions of syndecan-1 in disease. Matrix Biol. 31:3–16. 2012. View Article : Google Scholar : PubMed/NCBI
33	Fux L, Ilan N, Sanderson RD and Vlodavsky I: Heparanase: busy at the cell surface. Trends Biochem Sci. 34:511–519. 2009. View Article : Google Scholar : PubMed/NCBI
34	Huang MF, Zhu YQ, Chen ZF, et al: Syndecan-1 and E-cadherin expression in differentiated type of early gastric cancer. World J Gastroenterol. 11:2975–2980. 2005. View Article : Google Scholar : PubMed/NCBI
35	Conejo JR, Kleeff J, Koliopanos A, et al: Syndecan-1 expression is up-regulated in pancreatic but not in other gastrointestinal cancers. Int J Cancer. 88:12–20. 2000. View Article : Google Scholar : PubMed/NCBI
36	Wiksten JP, Lundin J, Nordling S, et al: Epithelial and stromal syndecan-1 expression as predictor of outcome in patients with gastric cancer. Int J Cancer. 95:1–6. 2001. View Article : Google Scholar : PubMed/NCBI
37	Vlodavsky I, Friedmann Y, Elkin M, et al: Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med. 5:793–802. 1999. View Article : Google Scholar : PubMed/NCBI
38	Naggi A, Casu B, Perez M, et al: Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting. J Biol Chem. 280:12103–12113. 2005. View Article : Google Scholar : PubMed/NCBI
39	Kato M, Wang H, Kainulainen V, et al: Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med. 4:691–707. 1998. View Article : Google Scholar : PubMed/NCBI